Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review
Introduction. Ocrelizumab is a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, which is approved for the treatment of the relapsing and primary progressive multiple sclerosis (MS). It is extremely rarely associated with late-onset neutropenia (LON), as an...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Serbian Medical Society
2022-01-01
|
| Edice: | Srpski Arhiv za Celokupno Lekarstvo |
| Témata: | |
| On-line přístup: | http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200042J.pdf |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|